Medicus Pharma (NASDAQ:MDCX) Now Covered by Analysts at D. Boral Capital

D. Boral Capital started coverage on shares of Medicus Pharma (NASDAQ:MDCX) in a research report report published on Monday morning,Benzinga reports. The firm issued a buy rating and a $14.00 target price on the stock.

MDCX has been the subject of a number of other reports. Brookline Capital Management upgraded Medicus Pharma to a “strong-buy” rating in a report on Monday, December 23rd. Maxim Group began coverage on Medicus Pharma in a research report on Tuesday, December 17th. They set a “buy” rating and a $10.00 price target for the company.

Medicus Pharma Stock Up 5.5 %

Medicus Pharma stock opened at $3.85 on Monday. The firm has a 50 day moving average of $3.50. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Friday, March 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. As a group, equities research analysts predict that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC bought a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma makes up approximately 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma as of its most recent filing with the Securities & Exchange Commission.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.